Skip to search formSkip to main contentSkip to account menu

vicrostatin

Known as: rCN+ peptide 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Disintegrins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Methods for Evaluation of a Snake Venom-Derived Disintegrin in Animal Models of Human Cancer.
Integrin targeting has been shown to be an effective approach for anticancer therapy. We engineered a recombinant disintegrin… 
2016
2016
A Novel, Non-Cytotoxic, Anti-Invasive Therapeutic Agent for Ovarian Cancer
The 5-year survival is only about 30% when ovarian cancer (OC) is first detected at an advanced stage, which is the case for ~70… 
2015
2015
Abstract POSTER-THER-1432: Intraperitoneal delivery of the disintegrin vicrostatin (VCN) effectively limits ovarian cancer growth and progression
Abstracts: 10th Biennial Ovarian Cancer Research Symposium; September 8-9, 2014; Seattle, WA Although prevention and early… 
2014
2014
Multimeric Disintegrin Protein Polymer Fusions That Target Tumor Vasculature
Recombinant protein therapeutics have increased in number and frequency since the introduction of human insulin, 25 years ago… 
2013
2013
Effect of vicrostatin on integrin based signaling molecules in cancer
2012
2012
Abstract A14: A novel integrin-targeted therapeutic agent for prostate cancer with anti-tumor/anti-angiogenic activity
Contortrostatin (CN), an anti-invasive/anti-angiogenic protein and member of the disintegrin family is a homodimeric protein that… 
2012
2012
Abstract 5248: A novel ovarian cancer imaging agent based on integrin ligation
Ovarian cancer diagnosis and subsequent evaluation of disease progression is difficult due to the location of tumor mass and… 
2010
2010
Development of a Multifaceted Ovarian Cancer Imaging Agent
Abstract : Ovarian cancer (OC) is the deadliest of all gynecological cancers, with five year survival rates of 45%. One critical… 
2010
2010
Mechanistic studies of the disintegrin contortrostatin and characterization of the recombinant protein vicrostatin
2009
2009
Development of a Multifaceted Ovarian Cancer Therapeutic and Imaging Agent
Abstract : Ovarian cancer (OC) is the deadliest of all gynecological cancers, with five year survival rates of <45%. One critical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)